WILMS’ TUMOR: INTEGRATING GENETIC INSIGHTS WITH CLINICOPATHOLOGICAL FEATURES FOR BETTER PROGNOSIS

Wilms’ tumor, also known as nephroblastoma, is the most common primary malignant renal tumor in children, accounting for approximately 5-6% of all childhood cancers. It is an embryonal tumor thought to arise from primitive metanephric blastema, presenting predominantly in early childhood, with a peak incidence between 2 and 5 years of age. Significant advancements in understanding its genetics, pathology, and treatment have dramatically improved patient outcomes over recent decades, transforming a once fatal diagnosis into a highly curable disease for most children.

Genetics of Wilms’ Tumor

The genetic landscape of Wilms’ tumor is intricate, characterized by a combination of germline and somatic mutations in various genes, often aligning with Knudson’s “two-hit” hypothesis for tumor suppressor genes. This model posits that two inactivating events are required for tumor development: the first hit can be inherited (germline) or acquired (somatic), while the second is an acquired somatic mutation.

• WT1 (Wilms Tumor 1) Gene: Located on chromosome 11p13, WT1 is a tumor suppressor gene encoding a zinc-finger transcription factor crucial for normal renal and gonadal development. Mutations or deletions in WT1 are found in approximately 10-15% of sporadic Wilms’ tumors and are strongly associated with specific syndromic forms:
  • WAGR Syndrome: Characterized by Wilms’ tumor, Aniridia (absence of iris), Genitourinary anomalies, and intellectual disability (formerly mental Retardation). This syndrome results from a contiguous gene deletion on 11p13 encompassing WT1 and PAX6.
  • Denys-Drash Syndrome (DDS): Caused by germline dominant-negative missense mutations in WT1, leading to a high risk of Wilms’ tumor, diffuse mesangial sclerosis (a type of kidney disease), and male pseudohermaphroditism.
  • Frasier Syndrome (FS): Also due to specific WT1 splice-site mutations, resulting in focal segmental glomerulosclerosis and gonadoblastoma, with a lower but still significant risk of Wilms’ tumor compared to DDS.
• WTX (Wilms Tumor on X-chromosome) Gene: Located on Xq11.1, WTX is another tumor suppressor gene implicated in Wilms’ tumorigenesis. Mutations or deletions in WTX are found in up to 20-30% of sporadic Wilms’ tumors, particularly in females due to X-inactivation patterns. It is believed to regulate Wnt signaling by targeting β-catenin for degradation.
• CTNNB1 (β-catenin) Gene: This gene, located on 3p21, encodes β-catenin, a key component of the Wnt/β-catenin signaling pathway, which is vital for cell proliferation and differentiation. Activating mutations in CTNNB1 are found in about 15% of Wilms’ tumors, leading to an accumulation of β-catenin and aberrant activation of Wnt target genes, promoting cell growth. These mutations are often mutually exclusive with WTX mutations, highlighting their common pathway involvement.
• TP53 (Tumor Protein 53) Gene: Situated on 17p13.1, TP53 is a critical tumor suppressor gene often mutated in many adult cancers. In Wilms’ tumor, TP53 mutations are less common in favorable histology tumors but are significantly prevalent (up to 70%) in anaplastic Wilms’ tumors, strongly correlating with chemotherapy resistance and worse prognosis. Germline TP53 mutations are associated with Li-Fraumeni syndrome, which includes an increased risk of various cancers, including Wilms’ tumor.
• IGF2 (Insulin-like Growth Factor 2) Gene and H19 (H19 Imprinted Maternally Expressed Transcript) Gene: Located on 11p15.5, this imprinted region is critical for growth regulation. Loss of imprinting (LOI) of IGF2 and/or H19 is observed in a significant proportion (approximately 70%) of Wilms’ tumors. This epigenetic alteration leads to biallelic expression of IGF2, a potent mitogen, contributing to tumor growth. This region is also implicated in Beckwith-Wiedemann Syndrome (BWS), characterized by overgrowth, macroglossia, omphalocele, and an increased risk of Wilms’ tumor.
• SIX1/SIX2 Genes: The Sine oculis homeobox (SIX) family genes, SIX1 and SIX2, found on 14q13 and 10q21, respectively, are transcription factors involved in renal development. Overexpression of SIX1 and SIX2 or mutations leading to their activation are found in some Wilms’ tumors, often promoting the maintenance of the undifferentiated blastemal cell state.
• Epigenetic Modifications: Beyond gene mutations, epigenetic changes, such as DNA methylation and histone modifications, play a role. Abnormal methylation patterns can silence tumor suppressor genes or activate oncogenes, contributing to uncontrolled cell proliferation.

Understanding the specific genetic drivers is increasingly important for risk stratification and potentially for targeted therapies, particularly in recurrent or refractory cases.

Clinicopathological Features of Wilms’ Tumor

Wilms’ tumor typically manifests with a range of clinical and pathological characteristics that guide diagnosis and management.

1. Clinical Presentation

• Age of Onset: Most commonly diagnosed in children aged 2-5 years, with a slight female predominance. Bilateral tumors and those associated with congenital syndromes tend to present at an earlier age.
• Abdominal Mass: The most frequent presenting symptom (80-90%) is an asymptomatic, palpable abdominal mass, often discovered incidentally by a parent during bathing or by a physician during a routine check-up. The mass is usually firm, smooth, and non-tender, rarely crossing the midline, differentiating it from neuroblastoma.
• Abdominal Pain: Present in about 30-40% of cases, often due to rapid tumor growth, hemorrhage, or rupture.
• Hematuria: Microscopic or gross hematuria occurs in 10-25% of patients, indicating tumor invasion into the collecting system.
• Hypertension: Found in 25% of cases, attributed to renal ischemia activating the renin-angiotensin system or compression of renal arteries by the tumor.
• Fever: Occurs in approximately 10% of cases, possibly due to tumor necrosis or infection.
• Other Symptoms: Anorexia, weight loss, malaise, and anemia are less common but can be present.
• Associated Congenital Anomalies and Syndromes:
  • WAGR Syndrome: As discussed (aniridia, genitourinary anomalies, intellectual disability).
  • Denys-Drash Syndrome and Frasier Syndrome: As discussed (renal failure, ambiguous genitalia).
  • Beckwith-Wiedemann Syndrome (BWS): Characterized by macrosomia, macroglossia, hemihypertrophy, omphalocele, umbilical hernia, ear creases/pits, and an increased risk of Wilms’ tumor (up to 10%). Usually associated with dysregulation of the 11p15.5 imprinted region.
  • Perlman Syndrome: A rare overgrowth syndrome with renal dysplasia, distinct facial features, and a very high risk of nephroblastomatosis and Wilms’ tumor.
  • Other anomalies include congenital heart disease, hypospadias, cryptorchidism, and isolated hemihypertrophy.

2. Diagnosis

• Imaging:
  • Ultrasound: Often the initial imaging modality, identifying a solid renal mass and assessing the contralateral kidney.
  • CT Scan (Computed Tomography) with Contrast: Provides detailed anatomical information, defines tumor size and extent, evaluates involvement of renal vessels, lymph nodes, and liver, and screens for lung metastases.
  • MRI (Magnetic Resonance Imaging): Useful for assessing tumor thrombus in the renal vein or inferior vena cava and for cases where radiation exposure needs to be minimized.
  • Chest X-ray/CT Chest: Essential for ruling out pulmonary metastases, which are common.
• Biopsy: The approach to biopsy varies globally.
  • SIOP (International Society of Paediatric Oncology) Protocol: Favors a pre-chemotherapy biopsy (or fine-needle aspiration) to confirm diagnosis, followed by neoadjuvant chemotherapy, then surgery. This approach aims to shrink the tumor, making surgery less invasive and reducing tumor spillage.
  • NWTS/COG (National Wilms Tumor Study Group/Children’s Oncology Group) Protocol: Traditionally favored upfront nephrectomy without a pre-operative biopsy if imaging is highly suggestive of Wilms’ tumor, followed by adjuvant chemotherapy based on surgical staging and pathology. This minimizes the risk of tumor dissemination from biopsy. Consensus is moving towards diagnostic biopsy for high-risk features.
• Lab Tests: Routine blood counts (may show anemia), renal function tests, and urinalysis. Elevated urinary vanillylmandelic acid (VMA) and homovanillic acid (HVA) are usually negative, helping differentiate Wilms’ from neuroblastoma.

3. Pathological Features (Gross)

Upon surgical resection, Wilms’ tumors typically present with characteristic gross features:

• Size and Shape: Often large, ranging from a few centimeters to occupying most of the renal cavity, sometimes weighing several kilograms. They are usually solitary, but multifocal or bilateral tumors occur in about 5-10% of cases.
• Encapsulation: Generally well-circumscribed, often surrounded by a pseudocapsule of compressed renal parenchyma. However, local invasion, especially into the renal sinus, renal vein, or perirenal fat, can occur.
• Cut Surface: Highly variable and variegated, appearing grey-white to tan, moist, and often bulging. Areas of hemorrhage, necrosis (yellow-white and friable), and cystic degeneration are common, reflecting rapid growth and inadequate blood supply. Foci of calcification are rare.
• Relationship to Kidney: The tumor typically arises within the renal parenchyma, distorting the kidney’s normal architecture. Normal renal tissue may be compressed or splayed around the tumor.

Morphology of Wilms’ Tumor

The microscopic morphology of Wilms’ tumor is diagnostic and crucial for prognostic stratification, particularly the presence or absence of anaplasia. The classic Wilms’ tumor, known as “favorable histology” (FH), exhibits a triphasic pattern, recapitulating various stages of embryonic kidney development.

1. Triphasic Pattern (Favorable Histology)

This characteristic pattern consists of three distinct cellular components, though their proportions can vary significantly, and one component may predominate or be absent:

• Blastemal Component:
  • Description: Composed of small, round to oval, undifferentiated cells with scant cytoplasm, primitive nuclei, and prominent nucleoli, resembling metanephric blastema. They are hyperchromatic and mitotically active.
  • Arrangement: Can occur in diffuse sheets, small aggregates, cords, or small, poorly defined tubules. Sometimes form rosettes or glomeruli-like structures.
  • Significance: Represents the primitive mesenchymal cells that differentiate into epithelial and stromal elements. When blastemal predominance is extensive and diffuse, it can be a predictor of less favorable response to chemotherapy.
• Stromal Component:
  • Description: Consists of spindle-shaped cells embedded in a myxoid or collagenous extracellular matrix. These cells represent differentiating mesenchymal elements.
  • Differentiation: The stromal component can differentiate remarkably into various mature or immature mesenchymal tissues, including:
    • Fibrous tissue: Collagenous stroma.
    • Smooth muscle: Bundles of spindle cells with eosinophilic cytoplasm.
    • Skeletal muscle: Rhabdomyomatous differentiation, characterized by large, eosinophilic cells with cross-striations (rhabdomyoblasts).
    • Cartilage: Islands of chondroid matrix with chondrocytes.
    • Bone: Osteoid formation.
    • Adipose tissue: Fat cells.
  • Significance: The presence of extensive heterologous differentiation (e.g., rhabdomyomatous) does not change the favorable prognosis of classic Wilms’ tumor.
• Epithelial Component:
  • Description: Represents differentiating renal epithelial structures, often resembling primitive tubules and glomeruli.
  • Differentiation:
    • Primitive tubules: Small, round, or elongated structures lined by cuboidal cells, often resembling early fetal tubules.
    • Primitive glomeruli: Ball-like structures resembling developing renal corpuscles.
    • Mature tubules: More well-formed tubules.
    • Cysts: Dilated tubular structures.
    • Papillary or glandular structures: Less common but can be present.
  • Significance: Indicates the potential for normal renal differentiation from the primitive blastema.

2. Anaplastic Morphology

Anaplasia is the most critical microscopic feature for prognostic assessment in Wilms’ tumor, indicating unfavorable histology (UH). It describes a profound degree of cellular atypia and is associated with resistance to conventional chemotherapy and a higher risk of relapse and mortality.

• Histological Criteria: Anaplasia is defined by the presence of:
  • Nuclear enlargement: Nuclei that are at least three times the diameter of adjacent, non-anaplastic tumor nuclei.
  • Nuclear hyperchromasia: Abnormally dark staining of nuclei.
  • Nuclear pleomorphism: Variation in nuclear size and shape.
  • Abnormal multipolar mitotic figures: Irregular and atypical mitotic activity.
• Classification:
  • Focal Anaplasia (FA): Anaplasia is confined to one or more discrete foci within the tumor. While still considered an adverse feature, the prognosis is better than for diffuse anaplasia.
  • Diffuse Anaplasia (DA): Anaplasia is widespread throughout the tumor or present in multiple discrete foci in different sections. This confers a significantly worse prognosis.

3. Nephrogenic Rests

Nephrogenic rests (NRs) are persistent foci of immature renal tissue that resemble fetal kidney and are widely considered precursor lesions to Wilms’ tumor. They are found in approximately 30-40% of kidneys resected for Wilms’ tumor and in most cases of bilateral Wilms’ tumors.

• Classification:
  • Perilobar Nephrogenic Rests (PLNRs): Located at the periphery of the renal lobules, typically round or oval. Associated with overgrowth syndromes (e.g., BWS).
  • Intralobar Nephrogenic Rests (ILNRs): Located within the renal lobules, often irregularly shaped. Associated with Wilms’ tumor syndromes related to WT1 mutations (e.g., WAGR, Denys-Drash).
• Significance: Their presence suggests a higher risk of developing multifocal or bilateral Wilms’ tumors and necessitates close monitoring of the contralateral kidney.

Prognosis of Wilms’ Tumor

The prognosis of Wilms’ tumor has remarkably improved, with overall survival rates exceeding 90% in many favorable histology cases. However, prognosis is significantly influenced by several key factors.

1. Staging

Tumor stage is the most crucial prognostic indicator, defined at the time of surgery (NWTS/COG) or after neoadjuvant chemotherapy (SIOP).

• NWTS/COG Surgical Staging System (Stages I-V):
  • Stage I (40-45%): Tumor limited to the kidney and completely resected; margins are negative; renal capsule intact; no involvement of renal sinus vessels; no tumor spillage. Excellent prognosis (>95% OS).
  • Stage II (20-25%): Tumor extends beyond the kidney but is completely resected; may involve renal capsular invasion, perirenal fat, or renal sinus vessels; margins negative. Good prognosis (>90% OS).
  • Stage III (20-25%): Residual non-hematogenous tumor confined to the abdomen; positive lymph nodes; tumor spillage; tumor in surgical margins; or tumor not completely resected. Worse prognosis (approx. 80-85% OS).
  • Stage IV (10-15%): Hematogenous metastases to distant sites (e.g., lung, liver, bone, brain). Poor prognosis (approx. 60-70% OS).
  • Stage V (5-10%): Bilateral renal involvement at diagnosis. Each kidney is staged independently, and overall treatment is complex. Varies greatly based on individual kidney stages.
• SIOP Staging System: In the SIOP approach, staging is performed post-neoadjuvant chemotherapy and surgery, but the principles of tumor extent remain similar in terms of local residual disease and metastases.

2. Histology

• Favorable Histology (FH): The classic triphasic or monophasic tumors without anaplasia. Represents 90-95% of Wilms’ tumors and has an excellent prognosis with current multimodal therapy (overall survival >90%).
• Anaplastic Histology (AH):
  • Focal Anaplasia: Carries a higher risk of relapse and slightly poorer survival compared to FH, but significantly better than diffuse anaplasia, especially if localized to Stage I or II.
  • Diffuse Anaplasia: The most significant adverse histological feature, associated with resistance to conventional chemotherapy and a substantially worse prognosis (overall survival 60-80%), requiring intensified treatment regimens.

3. Genetic Factors

Specific genetic alterations are increasingly recognized as independent prognostic markers:

• Loss of Heterozygosity (LOH) at 1p and 16q: These chromosomal losses are associated with a higher risk of relapse and worse event-free survival in favorable histology Wilms’ tumors, particularly for Stage I and II diseases, and can prompt treatment intensification.
• TP53 Mutations: Strongly correlated with anaplastic histology and are significant predictors of poor response to therapy and inferior outcomes.
• MYCN Amplification: Though rare, it has been linked to aggressive disease.
• Specific WT1 mutations might also influence drug sensitivity.

4. Treatment Response

• Response to Neoadjuvant Chemotherapy (SIOP Protocol): A significant reduction in tumor volume after pre-operative chemotherapy is associated with better surgical outcomes and prognosis. Lack of response can indicate resistant disease.
• Treatment Stratification: Modern protocols stratify treatment intensity based on stage and histology, ensuring that patients with higher-risk disease receive more aggressive therapy (e.g., higher doses of vincristine, dactinomycin, doxorubicin, cyclophosphamide, and radiation therapy).

5. Other Prognostic Factors

• Age at Diagnosis: Younger children (e.g., less than 2 years old) often have a slightly better prognosis, possibly due to more favorable biology.
• Tumor Size and Weight: While not independent prognostic factors, very large tumors can complicate surgery and may correlate with advanced stage.
• Lymph Node Involvement: The presence of positive regional lymph nodes classifies the tumor as Stage III and is a strong adverse prognostic indicator.
• Metastasis: Any distant metastasis immediately designates the tumor as Stage IV and significantly worsens prognosis. The specific site of metastasis (e.g., liver vs. lung) can also influence outcomes.

Conclusion

Wilms’ tumor represents a triumph of modern pediatric oncology. A comprehensive understanding of its genetic underpinnings, varied clinical presentations, characteristic gross and microscopic morphology (especially the triphasic pattern and the critical distinction of anaplasia), and the myriad prognostic factors has paved the way for highly effective, risk-adapted treatment strategies. While the majority of children with favorable histology and early-stage disease achieve excellent long-term survival, ongoing research into the molecular biology of anaplastic and relapsed tumors continues to seek novel therapeutic targets, aiming to improve outcomes for all affected children. The journey from initial diagnosis through personalized treatment and long-term follow-up underscores the critical importance of a multidisciplinary approach in managing this complex childhood cancer.

References:

1. Breslow, N. E., et al. (2006). Prognostic factors for Wilms’ tumor: results from the National Wilms’ Tumor Study Group. Journal of Clinical Oncology, 24(16), 2826-2834.
2. Dome, J. S., & Graf, N. (2018). Wilms tumor. Pediatric Clinics of North America, 65(3), 447-462.
3. Ehrlich, P. F., et al. (2018). Results of the Children’s Oncology Group A5056 Trial for Patients With Favorable Histology Wilms Tumor and Stage I/II Disease Treated With Dactinomycin and Vincristine. Journal of Clinical Oncology, 36(16), 1636-1641.
4. Fukuzawa, R., et al. (2016). Recent advances in the pathology of Wilms’ tumor. Pediatric International, 58(2), 79-87.
5. Gonzalez-Crussi, F., & Sarnat, H. B. (2018). Wilms’ tumor and other pediatric renal tumors. In Histopathology of Childhood Tumors (pp. 531-561). Springer, Cham.
6. Grundy, P. E., et al. (2005). Clinicopathologic features and outcome of diffuse anaplasia on initial tumor sampling in Wilms tumor: a report from the Children’s Oncology Group. Cancer, 104(12), 2900-2909.
7. Koesters, R., et al. (2004). WTX is a novel tumor suppressor gene on the X chromosome inactivated in Wilms tumor. Genes & Development, 18(11), 1289-1294.
8. Mahamdallie, S., et al. (2017). Constitutional TP53 Germline Mutations in Children with Wilms Tumor. Journal of Clinical Oncology, 35(15), 1735-1744.
9. Ooms, A. H. G., et al. (2016). Prognostic factors in Wilms’ tumor: a comprehensive review. Pediatric Blood & Cancer, 63(1), 159-166.
10. Pein, M., et al. (2014). Clinical and biological features of Wilms tumor with SIX1 and SIX2 overexpression. Genes, Chromosomes and Cancer, 53(9), 740-750.
11. Pind, M. T., et al. (2019). The molecular landscape of Wilms tumor. Cancer Genetics, 239, 13-23.
12. Rivera, M. N., et al. (2007). Inactivating mutations of WTX in Wilms’ tumor. Science, 315(5812), 642-645.
13. Scott, R. H., et al. (2008). Wilms tumor. Lancet Oncology, 9(9), 830-835.
14. Spreafico, F., et al. (2019). Wilms tumor. Cancers (Basel), 11(11), 1734.
15. Vujanić, G. M., et al. (2016). The International Society of Paediatric Oncology (SIOP) approach to Wilms tumour: a 50-year consensus. Nature Reviews Clinical Oncology, 13(10), 670-676.